The US Specialty Pharmaceutical Market: Industry Analysis & Outlook (2017-2021)

1
Industry Research by Koncept Analytics
The US Specialty Pharmaceutical Market Industry
Analysis Outlook-------------------------------
---------- (2017-2021)
December 2017
2
Executive Summary
The US pharmaceutical market is segregated into
two types of drugs majorly i.e. traditional drugs
and specialty drugs. Specialty drugs in recent
times have gained a strong foothold in the US and
are likely to experience robust growth in the
coming years, with majority of the pharmaceutical
companies heading their research and development
initiatives towards these drugs. Specialty drugs
are basically meant for chronic and rare disease.
Drugs in this category are very expensive and
difficult to administer. Also, these drugs
require proper management and special handling
making them costly. Since, a large part of
population in the US is ageing into diseases like
cancer, and other deadly diseases, the demand for
specialty drugs has skyrocketed in recent times.
The US specialty pharmaceutical market has
changed over the span of five years with a lot of
these drugs being in their final phase of
development. The US specialty pharmaceutical
market is likely to grow at staggering growth
rate in the coming years majorly due to factors
like ageing population of the US, improving life
expectancy, rise in real net per capita medicine
spending on specialty drugs, and high prevalence
of chronic disease in the region. The market is
also undergoing some notable changes that have
been covered in the report. The market growth is
likely to be hindered by abandonment rate of
specialty medicines and high RD costs. The
report offers an in-depth analysis of the The US
Specialty Pharmaceutical Market Industry
Analysis Outlook (2017-2021). Major
pharmaceutical companies that have been covered
in the report include Celgene Corporation, Gilead
Sciences Inc., Amgen Inc., AbbVie Inc..
3
There are a number of factors that aided growth
of US specialty drugs market, but drug price was
a key factor, which resulted in increased
revenues.
The US Pharmaceutical Market by Value (2012-2016)

• The US pharmaceutical market was recorded at
  US.. billion in 2016, increasing from US..
  billion in the previous fiscal year. The market
  over the span of five years grew at a CAGR of ..
  for the period spanning 2012-2016.
• Specialty drugs are expected to account for ..
  of the market revenues in the US in year 2021.
  This share is likely to increase by .. from
  2016.
• In 2016, FDA approved .. of new molecules in the
  specialty drugs category amongst which .. were
  from xx segment. The remaining .. drug approvals
  or new molecule base was of traditional drugs.

The US Pharmaceutical Market by Segment Forecast
(2021)
The US Pharmaceutical Markets Drug Approval by
Segment (2016)
4
The US pharmaceutical market is expected to see a
continuous shift from traditional drugs to
specialty drugs.
The US Specialty Pharmaceutical Market by Value
(2012-2016)

• The specialty pharmaceutical market was valued at
  US.. billion in 2016, increasing from US..
  billion in 2012. The market grew at a CAGR of ..
  for the period spanning 2012-2016.
• The total prescription volume of specialty drugs
  in the US is anticipated to reach .. million mark
  by 2021, increasing from .. million in 2017.
• Oncology is expected to remain on the top with
  the prescription volume anticipated to reach
  billion mark by 2021, followed by MS with total
  prescription volume reaching million.

The US Specialty Medication Prescription Volume
Forecast by Therapeutic Class (2021)
The US Specialty Medication Prescription Volume
(2012-2016)
5
For Report Purchase Click Belowhttp//www.koncep
tanalytics.com/Researchreport/the-us-specialty-pha
rmaceutical-market-industry-analysis-outlook-2017-
2021-29471.aspx
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9871694789vikas_at_konceptana
lytics.com
www.konceptanalytics.com